Neuronetics (STIM) Set to Announce Quarterly Earnings on Tuesday

Neuronetics (NASDAQ:STIM) will post its quarterly earnings results before the market opens on Tuesday, November 12th. Analysts expect Neuronetics to post earnings of ($0.23) per share for the quarter. Neuronetics has set its FY 2024 guidance at EPS and its Q3 2024 guidance at EPS.Persons that wish to listen to the company’s earnings conference call can do so using this link.

Neuronetics (NASDAQ:STIM) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.06). Neuronetics had a negative net margin of 45.06% and a negative return on equity of 109.00%. The firm had revenue of $16.45 million for the quarter, compared to the consensus estimate of $18.76 million. During the same quarter in the prior year, the company earned ($0.17) earnings per share. On average, analysts expect Neuronetics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Neuronetics Stock Up 8.3 %

Shares of NASDAQ STIM opened at $1.17 on Friday. The firm has a fifty day simple moving average of $0.90 and a two-hundred day simple moving average of $1.60. The firm has a market capitalization of $35.46 million, a PE ratio of -1.04 and a beta of 2.21. The company has a current ratio of 2.58, a quick ratio of 2.37 and a debt-to-equity ratio of 2.38. Neuronetics has a 12 month low of $0.66 and a 12 month high of $5.07.

Insider Transactions at Neuronetics

In other Neuronetics news, Director Robert Cascella acquired 35,000 shares of the company’s stock in a transaction dated Friday, August 16th. The stock was purchased at an average price of $1.06 per share, with a total value of $37,100.00. Following the completion of the purchase, the director now directly owns 349,098 shares in the company, valued at approximately $370,043.88. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders bought a total of 211,776 shares of company stock valued at $175,170 over the last three months. Corporate insiders own 9.80% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on STIM. Canaccord Genuity Group cut their target price on Neuronetics from $6.00 to $3.00 and set a “buy” rating on the stock in a research note on Tuesday, August 13th. William Blair reissued a “market perform” rating on shares of Neuronetics in a research report on Monday, August 12th. Finally, JMP Securities decreased their target price on shares of Neuronetics from $7.00 to $3.00 and set a “market outperform” rating for the company in a report on Wednesday, August 14th.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.